What would a migraine headache look like as art? That’s what Allergan is asking sufferers in a new campaign for chronic migraine awareness.

Neurocrine is out with its price for Ingrezza—and it’s even higher than some industry watchers expected.

Investors were in the mood for good news from Eli Lilly—and they got a bit of it in its first-quarter earnings report, even as pipeline worries cast a cloud…

Sanofi has ratcheted up the legal pressure on Mylan with a lawsuit claiming the EpiPen maker abused its monopoly position to “squelch” competition, including…

Analysts question whether positive survival data for Lilly's abemaciclib will be enough to help the third-to-market med hang with its competition.…

Children with a rare, devastating brain disease may soon have their first treatment option in BioMarin’s Brineura.

Klick Health's Klick Labs created a programmable device that simulates Parkinson's disease tremors in a bid to create empathy and study its effect on…

Allergan’s new "Toilet Talk" campaign seeks to normalize bowel health conversations—and the more candid, the better.

Valeant unveiled the sticker on its new psoriasis drug Siliq—and at $3,500 per month it’s the lowest for next-gen meds.

Marketing